On the other hand, rebamipide is also a quinolinone derivative with mucin secretagogue activity and rebamipide ophthalmic suspension (Mucosta ophthalmic suspension UD2 %; Otsuka Pharmaceutical Co. Tokyo, Japan) was recently approved for the treatment of dry eye in Japan. This evidence concerns the gene MUC5AC and dry eye syndrome.